Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
354 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Currently Recruiting (2)
  • Closed (1)

Medical Condition

  • Show all (41)
  • Cancer (26)
    • Bladder Cancer (1)
    • Brain Cancer (4)
    • Breast Cancer (7)
    • Gastrointestinal (1)
    • Gynecologic Cancer (3)
    • Lung Cancer (5)
    • Pancreatic Cancer (2)
    • Skin Cancer (2)
      • (-) Melanoma (2)
  • Eye (1)
  • Healthy Volunteers (1)
  • Heart Disease (2)
  • (-) Infectious Disease (1)
    • Lyme Disease (1)
  • Neurological Disorders (3)
  • Obesity (1)
  • Pediatrics (4)
  • Surgery (1)
  • Transplant (1)
Displaying 1 - 3 of 3

Study of V940 Plus Pembrolizumab in Patients With High-Risk Melanoma

Condition: Skin Cancer / Melanoma
Investigator: Benjamin Izar, MD
Status: Currently Recruiting
The purpose of this study is to compare V940 plus pembro given after surgery to a placebo plus pembro given after surgery and to study how effective the study drug is. A placebo looks like a study drug, but it has no active ingredients. V940 has not yet been approved by the Food and Drug…
Read More

Vagus Nerve Stimulation: A New Treatment Study for Previously Treated Lyme Disease Patients with Persistent Symptoms

Condition: Infectious Disease / Lyme Disease
Investigator: Brian Fallon, MD
Status: Currently Recruiting
Are you suffering from persistent symptoms that began after you were diagnosed and treated with antibiotics for Lyme Disease? This new research study aims to test a new form of treatment for people with persistent symptoms despite antibiotic treatment for Lyme disease. This treatment involves stimulating a nerve on the surface of your ear. This is called…
Read More

Study of Fianlimab and Cemiplimab vs. Pembrolizumab in Patients with Resected High-Risk Melanoma

Condition: Skin Cancer / Melanoma
Investigator: Benjamin Izar, MD
Status: Closed
The purpose of this study is to see if the combination of fianlimab (REGN3767) and cemiplimab (REGN2810) is an effective treatment compared to pembrolizumab in participants that have had melanoma removal surgery but are still at high risk for the return of the disease. This study involves 2 study drugs: fianlimab (REGN3767)…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science